In short
AZD4144 is an investigational chemical substance being developed by AstraZeneca AB for adults with acute kidney injury caused by sepsis. The only registered trial is a Phase 2 study with 124 participants, currently authorised to start, testing the drug given as an intravenous infusion against a placebo. The trial measures how well AZD4144 improves creatinine clearance, a key indicator of kidney function, over 24 hours.
Key points
- AZD4144 is being studied in sepsis-associated acute kidney injury (AKI), a serious condition where the kidneys suddenly fail during a bloodstream infection.
- The only registered trial is a Phase 2 study with 124 participants, currently authorised to begin.
- AZD4144 is given as an intravenous infusion, compared against a placebo.
- The main measurement is creatinine clearance (CrCl), which shows how well the kidneys are filtering waste from the blood.
- The substance is investigational, with no marketing authorisation in the product records.
What is AZD4144?
AZD4144 is a chemically synthesised substance, meaning it is a small-molecule drug made in a laboratory rather than derived from a living organism. It is being developed by AstraZeneca AB and appears in the trial record only under its development code, AZD4144, with no other trade names or alternative names listed. The product records show that AZD4144 has no marketing authorisation in any country, which means it is an investigational substance and cannot yet be prescribed outside of clinical trials.
In the registered trial, AZD4144 has the role of the test substance, meaning it is the active drug being investigated, while a placebo serves as the comparison arm.
How does AZD4144 work?
The trial records do not describe the molecular target or mechanism of action of AZD4144. What is known is the purpose of the research: to evaluate whether AZD4144 can improve creatinine clearance (CrCl), a measure of how effectively the kidneys filter waste products from the blood. In sepsis-associated acute kidney injury, kidney function drops suddenly, and creatinine clearance falls. The trial is designed to see whether AZD4144 can help restore this clearance.
Which conditions is AZD4144 studied for?
- Sepsis-associated acute kidney injury (AKI) — a serious complication of sepsis, a life-threatening response to infection, in which the kidneys suddenly stop working properly. This is the only condition in the registered trial.
How is AZD4144 given?
AZD4144 is prepared as a solution for infusion and is given by intravenous infusion, meaning it is delivered directly into a vein over a period of time. The trial record lists the dose as 00 mg, which indicates that the exact dose was not reported in the registry.
What do the clinical trials show?
There is one registered clinical trial for AZD4144, identified as 2025-522232-13-00 in the EU Clinical Trials Information System (CTIS). It is a Phase 2, interventional study with a planned enrollment of 124 participants. The trial is currently authorised, meaning it has received regulatory approval to begin but has not yet reported results.
The trial is a randomised comparison: participants receive either AZD4144 or a placebo, both given by intravenous infusion. The main outcome measure is the Area Under the Curve (AUC) of 24-hour creatinine clearance. In plain words, this measures the total kidney filtering capacity over a full day after treatment, capturing both how high the clearance rises and how long any improvement lasts.
Because the study has not yet reported results, there are no efficacy findings to describe. The trial is designed to answer whether AZD4144 can improve kidney function in adults whose kidneys have been damaged by sepsis.
Who can take part in the trial?
The registered trial enrols adults with sepsis-associated acute kidney injury. The registry record does not list detailed inclusion or exclusion criteria such as age limits, kidney function thresholds, or specific sepsis definitions. Anyone interested in taking part would need to review the full trial protocol through the CTIS record.
What side effects are known?
No side effect information for AZD4144 is available in the trial registry or the product records. As an investigational substance in an early-phase trial, its safety profile is still being established, and the authorised Phase 2 study is designed in part to collect this information.